Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3511
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines.

    To find out more about Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
3SBio
A&G Pharmaceutical
AB Science
Abbott
AbbVie
Abiogen
AC Immune
Actelion
Active Biotech
Adaptimmune
Adherex
Advanced Life Sciences
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
ApopLogic Pharmaceuticals
Apotex
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Axelar
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
Betapharma
Bio-Medisinsk Innovasjon
BioAlliance Pharma
Biogen Idec
Biokine Therapeutics
BioLineRx
BioNTech
BioNumerik
BioSante
Biosceptre
Biostar
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
CanBas
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celgene
Cell Therapeutics
Celldex Therapeutics
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chong Kun Dang
Circadian Technologies
CJ Corp
Clavis Pharma
CLL Pharma
Coronado Biosciences
Cosmo Pharmaceuticals
CreaGene
Critical Outcome Technologies
CSL
Curaxis
CureTech
CureVac
Curis
Cyclacel
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DNAVEC
Dong-A
ECI
Eisai
Elara Pharmaceuticals
Eli Lilly
Endocyte
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Etubics
Exelixis
Flamel Technologies
Fresenius
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Generex
Genmab
GenOdyssee Pharmaceuticals
Genta
Genticel
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Gradalis
Hanmi
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intezyne Technologies
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kalypsys
Karyon-CTT
Kiadis
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Momotaro-Gene
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
NovaRx
Novogen
Oasmia
Oncalis
OncoGenex Pharmaceuticals
OncoMed
OncoMune
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Philogen
PhiloGene
Pierre Fabre
Piramal
Pro-Pharmaceuticals
Progen
Progen Pharmaceuticals
Progenics Pharmaceuticals
Protherics
Radient Pharmaceuticals
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
responsif
RESprotect
Rexahn
Rigel
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Sareum
Scancell
Seattle Genetics
ShimodaAtlantic Oncology
Shionogi
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Solbec Pharmaceuticals
Spirogen
SRI International
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
VBL Therapeutics
Vectura
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Virionics
ViroMed
WntResearch
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
York Pharma
Zensun
Zhejiang Beta Pharma
Zivena
Zydus Cadila
A Shortlist of Drugs Included are:
abagovomab
ADXS11-001
AE-37
AEB071
afatinib
aflibercept
agatolimod
AGS-003
aldesleukin
ALT-801
amrubicin hydrochloride
ANZ-207
APO-866
ARQ-197
ARRY-438162
astuprotimut-r
Auto TAG vaccine
AVX-701
axitinib
bardoxolone methyl
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
BIBF-1120
BMS-663513
BMS-936558
bortezomib
BP-GMAX-CD1
Buparlisib
BV-NSCLC-001
Cabozantinib
canfosfamide hydrochloride
CB-10-01
CDX-1307
celecoxib
cetuximab
CG-201
cilengitide
cositecan
CreaVax-PC
crizotinib
CT-011
CV-9103
CV-9201
CVac
dacomitinib
dasatinib
DCVax-prostate
decitabine
denenicokin
denileukin diftitox
dinaciclib
docetaxel
dovitinib lactate
E-75
E7449
EMD-273063
emepepimut-S
endostatin
entinostat
epirubicin
erlotinib
etoposide (1)
etoposide phosphate
everolimus
Exherin
fresolimumab
ganetespib
ganitumab
gefitinib
GI-4000
glembatumumab vedotin
golvatinib
GSK-1120212
GSK-2118436
GSK-2130579A
GV-1001
GVAX
GVX-3322
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
HS-110
icotinib hydrochloride
ICT-107
imatinib mesilate
imMucin
IMO-2055
INCB-24360
iniparib
interferon
interferon (gamma1b)
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
irinotecan hydrochloride
ISA-P53-01
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
Lambrolizumab
lapatinib ditosylate
LEE-011
lenvatinib
LGX818
LipoVIL12
MDX-1379
MetXia
MGN-1601
MKC-1106-MT
MORAb-004
motesanib diphosphate
MVA-BN Her-2 vaccine
nadroparin
necitumumab
nilotinib
nimotuzumab
oblimersen sodium
OncoVAX
Onyvax-105
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
P276-00
paclitaxel
paclitaxel polyglumex
pazopanib hydrochloride
peginterferon alfa-2b
pemetrexed disodium
perifosine
pimasertib
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
RAF-265
ramucirumab
retaspimycin
Reximmune-C
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
S-488410
sagopilone
sargramostim
SCIB-1
selumetinib
sipuleucel-T
sorafenib tosylate
sunitinib malate
Survivac
talactoferrin alfa
talminogene laherparepvec
tegafur + uracil
tesetaxel
TG-4010
thalidomide
thymalfasin
tipapkinogene sovacivec
topotecan
trabedersen
tremelimumab
TroVax
TS-1
velimogene aliplasmid
veliparib
vemurafenib
verpasep caltespen
verubulin
vinflunine ditartrate
vitespen
volociximab
VX-001
YM-155
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines.
    To find out more about Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Learn More


Triple Analysis: Melanoma, Angiogenesis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Learn More

Other selected research from the 'Oncology' category:


Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
This report comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. The report extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications. Learn More


Triple Analysis: Cancer Vaccines, Antibodies and Peptides
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Cancer Vaccines and by the two compound strategies of Antibodies and Peptides. Learn More